Cargando…
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
BACKGROUND: Women of childbearing potential are often treated with monoclonal antibodies to control chronic and debilitating inflammatory diseases. Remicade(®) (innovator infliximab [IFX]) may cross the placenta after the first trimester of pregnancy. Hence, evidence is needed to optimize treatment...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007430/ https://www.ncbi.nlm.nih.gov/pubmed/31677004 http://dx.doi.org/10.1007/s40264-019-00881-8 |